Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1496.13p Bid 1499.60p Ask 1500.00p Change 0.39%
Last Updated: 26/05/2018 01:14. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn.

Financial Highlights Year Ended 31/12/2017

Turnover
£30,186.00m
Operating Profit
£4,087.00m
Dividend Yield
5.31
Dividend Per Share
80.00
Dividend Cover
0.39
P/E Ratio
48.01

Key Personnel

Emma Natasha Walmsley
Chief Executive Officer
Simon Paul Dingemans
Chief Financial Officer
Sir Philip Roy Hampton
Non-Executive Chairman
Dr Patrick John Thompson Vallance
Non-Executive Director
Dr Vivienne Cox
Non-Executive Director
Dr Jesse Goodman
Non-Executive Director
Prof Sir Roy Malcolm Anderson
Non-Executive Director
Lynn Laverty Elsenhans
Non-Executive Director
Judith Carol Lewent
Non-Executive Director
Urs Rohner
Non-Executive Director
Manvinder Singh Banga
Non-Executive Director
Dr Laurie Hollis Glimcher
Non-Executive Director

Stock Details

EPIC
GSK
ISIN
GB0009252882
Shares in Issue
4,959,302,644
Market cap
£74,766.45m

Analyst Views (13)

Strong Buy
 
38.46%
Buy
 
0.00%
Hold
 
53.85%
Sell
 
0.00%
Strong Sell
 
7.69%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1500.00p
Bid Price
1499.60p
Ask Price
1500.00p
Volume
9571433
Change Today
5.80p
% Change Today
0.39%
Open
1496.00p
Previous Close
1500.00p
Intraday High
1502.20p
Intraday Low
1488.40p
52 Week High
1724.50p
52 Week Low
1236.40p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

GlaxoSmithKline Intra-day Chart

GlaxoSmithKline News

News in this section is provided by MoneyAM

GlaxoSmithKline joint venture's HIV treatment approved in Europe 21 May 2018 | 13:20 Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC 27 Apr 2018 | 13:00 Broker Forecast - Berenberg issues a broker note on GlaxoSmithKline PLC 27 Apr 2018 | 12:30 Director Deals - GlaxoSmithKline PLC (GSK) 26 Apr 2018 | 17:40 Director Deals - GlaxoSmithKline PLC (GSK) 26 Apr 2018 | 17:35 Director Deals - GlaxoSmithKline PLC (GSK) 26 Apr 2018 | 17:35 Director Deals - GlaxoSmithKline PLC (GSK) 26 Apr 2018 | 17:35 Director Deals - GlaxoSmithKline PLC (GSK) 26 Apr 2018 | 17:35 Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLC 26 Apr 2018 | 16:20 Downbeat global performance stifles FTSE 25 Apr 2018 | 16:44 GlaxoSmithKline profit falls 38%, warns of asthma treatment sales slip 25 Apr 2018 | 13:22 GlaxoSmithKline IMPACT study shows significant benefits of Trelegy Ellipta for COPD patients 19 Apr 2018 | 07:51 Director Deals - GlaxoSmithKline PLC (GSK) 17 Apr 2018 | 14:50 Director Deals - GlaxoSmithKline PLC (GSK) 17 Apr 2018 | 14:50 Director Deals - GlaxoSmithKline PLC (GSK) 17 Apr 2018 | 14:50 Director Deals - GlaxoSmithKline PLC (GSK) 17 Apr 2018 | 14:40 Director Deals - GlaxoSmithKline PLC (GSK) 17 Apr 2018 | 14:40 Broker Forecast - Credit Suisse issues a broker note on GlaxoSmithKline PLC 03 Apr 2018 | 10:20 Broker Forecast - Kepler Cheuvreux issues a broker note on GlaxoSmithKline PLC 28 Mar 2018 | 10:30 Broker Forecast - HSBC issues a broker note on GlaxoSmithKline PLC 28 Mar 2018 | 09:10 Weaker pound and rally in mining stocks boost FTSE 27 Mar 2018 | 16:53 FTSE gains momentum from upbeat global performance 27 Mar 2018 | 12:00 GSK buys Novartis stake in consumer healthcare joint venture for $13bn 27 Mar 2018 | 07:23 FTSE struggles to gain ground against stronger pound 23 Mar 2018 | 16:46 GlaxoSmithKline says new HIV treatment gets European approval 23 Mar 2018 | 13:19 FTSE resilient as trade war fears hit global markets 23 Mar 2018 | 11:52 GlaxoSmithKline withdraws bid for Pfizer unit 23 Mar 2018 | 08:16 GlaxoSmithKline's Shingrix approved in Europe, Japan 23 Mar 2018 | 07:13 Broker Forecast - Morgan Stanley issues a broker note on GlaxoSmithKline PLC 22 Mar 2018 | 08:00 Broker Forecast - Societe Generale issues a broker note on GlaxoSmithKline PLC 14 Mar 2018 | 14:10

Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Tangible Assets
10,860.0
10,808.0
Intangible Assets & Goodwill
23,296.0
24,741.0
Investments & Other Non-Current Assets
6,318.0
6,821.0
Total Non-Current Assets
40,474.0
42,370.0
Inventory
5,557.0
5,102.0
Trade & Receivables
6,000.0
6,026.0
Cash & Receivables
3,833.0
4,897.0
Other Current Assets & Assets Held for Resale
517.0
686.0
Total Assets
56,381.0
59,081.0

Liabilities (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Short Term Liabilities
26,569.0
19,001.0
Long Term Liabilities
26,323.0
35,117.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
52,892.0
54,118.0

Net Assets (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Net Assets
3,489.0
4,963.0

Equity (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Share Capital
1,343.0
1,342.0
Minority Interests
3,557.0
3,839.0
Retained Earnings
-6,477.0
-5,392.0
Share Premium Account
3,019.0
2,954.0
Other Equity
2,047.0
2,220.0
Total Equity
3,489.0
4,963.0

Cashflow (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Cashflow from Operating Activities
6,918.0
6,497.0
Cashflow Before Financing
5,475.0
5,228.0
Increase / Decrease in Cash
-905.0
-1,164.0

Income (£m)

Data has been provided by MoneyAM

Reporting Date
31 Dec 2017
31 Dec 2016
Turnover
30,186.0
27,889.0
Cost of Sales
10,342.0
9,290.0
Gross Profit
19,844.0
18,599.0
Operating Profit
4,087.0
2,598.0
Pre-Tax Profit
3,525.0
1,939.0
Profit / Loss for the Year
2,169.0
1,062.0

Dividend History

Data has been provided by MoneyAM

Period
Ex-Dividend Date
Payment Date
H2 Dividend
22 Feb 2018
12 Apr 2018
Q3 Dividend
09 Nov 2017
11 Jan 2018
H1 Dividend
10 Aug 2017
12 Oct 2017
Q1 Dividend
11 May 2017
13 Jul 2017
H2 Dividend
23 Feb 2017
13 Apr 2017
Q3 Dividend
03 Nov 2016
12 Jan 2017
H1 Dividend
11 Aug 2016
13 Oct 2016
Q1 Dividend
12 May 2016
14 Jul 2016
Special Dividend
18 Feb 2016
14 Apr 2016
H2 Dividend
18 Feb 2016
14 Apr 2016
Q3 Dividend
12 Nov 2015
14 Jan 2016
H1 Dividend
13 Aug 2015
01 Oct 2015
Q1 Dividend
14 May 2015
09 Jul 2015
H2 Dividend
19 Feb 2015
09 Apr 2015
Q3 Dividend
06 Nov 2014
08 Jan 2015
H1 Dividend
06 Aug 2014
02 Oct 2014
Q1 Dividend
14 May 2014
10 Jul 2014
H2 Dividend
19 Feb 2014
10 Apr 2014
Q3 Dividend
13 Nov 2013
09 Jan 2014
H1 Dividend
07 Aug 2013
03 Oct 2013
Q1 Dividend
08 May 2013
11 Jul 2013
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.